Neuronetics Company Leadership
| STIM Stock | USD 1.30 0.03 2.36% |
Neuronetics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Neuronetics stock suggests that most insiders are panicking at this time. Neuronetics employs about 716 people. The company is managed by 15 executives with a total tenure of roughly 1671 years, averaging almost 111.0 years of service per executive, having 47.73 employees per reported executive.
Insider Sentiment
Mostly Selling
Selling | Buying |
Latest Trades
| 2026-02-26 | William Andrew Macan | Disposed 3427 @ 1.35 | View | ||
| 2026-02-12 | William Andrew Macan | Disposed 14120 @ 1.65 | View | ||
| 2026-02-10 | William Andrew Macan | Disposed 3485 @ 1.55 | View | ||
| 2025-05-12 | Stephen Furlong | Disposed 193460 @ 4.27 | View |
Following insider trading sentiment in Neuronetics can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Neuronetics | Build AI portfolio with Neuronetics Stock |
Neuronetics Management Team Effectiveness
The company has return on total asset (ROA) of -21.21 % which indicates that it has lost $21.21 on every $100 of assets deployed. This is much lower than what is typical in the sector. Similarly, it shows a return on stockholder's equity (ROE) of -218.99 %, which implies that the business failed to generate returns adequate to cover equity costs.As of yesterday, Common Stock Shares Outstanding is anticipated to decline to approximately 19.4 M. In addition to that, Net Loss is anticipated to decline to approximately -35.1 M
Stock Ownership Analysis
About 20.0% of the company outstanding shares are owned by corporate insiders. The book value of Neuronetics was at this time reported as 0.4. The company recorded a loss per share of 0.83. Neuronetics had not issued any dividends in recent years.Stock Institutional Investors
Institutional ownership matters in Neuronetics because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Fourworld Capital Management Llc | 2025-09-30 | 568 K | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 475.7 K | Renaissance Technologies Corp | 2025-12-31 | 474.9 K | Millennium Management Llc | 383.7 K | Northern Trust Corp | 2025-09-30 | 276.6 K | Jane Street Group Llc | 2025-09-30 | 234.6 K | Jbf Capital, Inc. | 2025-12-31 | 233.2 K | The Goldman Sachs Group Inc | 2025-09-30 | 221.9 K | Susquehanna International Group, Llp | 2025-09-30 | 220.6 K | Vanguard Group Inc | 2025-12-31 | 2.6 M | Balyasny Asset Management Llc | 2025-12-31 | 2.6 M |
Insider Trading Activities
Insider trading disclosures for Neuronetics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 88.69 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Neuronetics bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Shares in Circulation | First Issued 2018-09-30 | Previous Quarter 66 M | Current Value 67 M | Average Shares Outstanding 28.1 M | Quarterly Volatility 13.8 M |
Macro event markers
Neuronetics Stock Holders Distribution
Institutional ownership analysis for Neuronetics matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Neuronetics Market Cap and Value
Neuronetics Workforce Comparison
Neuronetics takes the leading position in number of employees compared to key competitors. The total workforce of Health Care industry is at this time estimated at about 2,932. Neuronetics totals roughly 716 in number of employees claiming about 24% of equities under Health Care sector.
Neuronetics Profit Margins
The company has Profit Margin (PM) of -34.0 %, which implies that it is absorbing losses on its sales activity. This is much lower than what is typical in the sector. Similarly, it shows Operating Margin (OM) of -20.0 %, which indicates that it has not achieved operational breakeven on its current revenue base.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.84 | 0.83 |
|
|
Neuronetics Insider Trading History
Insider trading disclosures for Neuronetics offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 88.69 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Neuronetics Notable Stakeholders
Stakeholders matter for Neuronetics because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Keith Sullivan | CEO President | Profile | |
| Stephen MS | Senior CEO | Profile | |
| Andrew JD | General VP | Profile | |
| MBA CMA | Chief Officer | Profile | |
| Lisa MetznerRosas | Senior Officer | Profile | |
| Andrew Macan | Gen VP | Profile | |
| Claire Sears | VP Marketing | Profile | |
| Rick Grubbs | Senior Accounts | Profile | |
| Cory Anderson | Senior Clinical | Profile | |
| Kara Thornton | VP Director | Profile | |
| Rusty Page | Senior Quality | Profile | |
| William Leonard | Chief Officer | Profile | |
| Geoffrey MD | Chief Officer | Profile | |
| Sara Grubbs | Senior Officer | Profile | |
| Jeffrey Jones | Senior Operations | Profile |
Management Information & Data Sources
Neuronetics is a micro-cap company in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Management quality is typically assessed through capital allocation choices and operating follow-through. CEO is Keith Sullivan with 716 employees and 15 reported executives.
Inputs for Neuronetics come from periodic company reporting and market reference feeds and are mapped into a consistent schema for analysis. Some fields can appear with publication lag. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsWorkforce Efficiency and Productivity
Investors reviewing Neuronetics can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Neuronetics Manpower Efficiency
Return on Neuronetics Manpower
| Revenue Per Employee | 104.6K | |
| Revenue Per Executive | 5M | |
| Net Loss Per Employee | 61.1K | |
| Net Loss Per Executive | 2.9M | |
| Working Capital Per Employee | 37.5K | |
| Working Capital Per Executive | 1.8M |
More Resources for Neuronetics Stock Analysis
Understanding Neuronetics typically begins with financial statements and long-term trend review. Ratio context helps frame profitability, efficiency, and growth trends for Neuronetics Stock. Outlined below are key reports that provide context for Neuronetics Stock:Neuronetics has a market cap of 88.69 M, operating margin of -19.63%, ROE of -2.19%. Review World Market Map for broader portfolio context. This reflects a position in Neuronetics within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. New to investing in Neuronetics Stock? Start with our How to Invest in Neuronetics Stock guide for a step-by-step overview.Analysis related to Neuronetics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Earnings Share -0.83 | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
Neuronetics's market price can diverge from book value, the accounting figure shown on Neuronetics's balance sheet. Neuronetics' market capitalization is 88.69 M. With a P/B ratio of 3.25, the market values Neuronetics well above its book equity. Enterprise value stands at 151.63 M. Intrinsic value reflects what Neuronetics' fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Neuronetics' value from its trading price, which are computed with different methods. For Neuronetics, key inputs include a P/B ratio of 3.25, a profit margin of -34.27%, ROE of -2.19%, and revenue of 74.89 M. The quoted price is simply the exchange level where supply meets demand.